News

Work carried out at the Breakthrough Breast Cancer Research Centre and at the Cancer Research UK Centre for Cancer Therapeutics, both of which are at The Institute of

Both companies believe that this hire will accelerate Focus Surgery’s (FSI’s) ability to expand its high intensity focused ultrasound (HIFU) technology platform. As the director of regulatory affairs,

Results show Cleviprex (clevidipine butyrate) injectable emulsion is safe and effective for managing blood pressure in patients undergoing cardiac surgery and provides more precise blood pressure control than

This was the third of several regularly scheduled reviews by the data safety monitoring board (DSMB) that will occur over the duration of the trial. The purpose of

Under the terms of the agreement, Lilly (through a wholly owned subsidiary) will acquire ImClone, followed by a merger of Lilly’s subsidiary with ImClone. Lilly is expected to

The authorization from Health Canada was based upon the safety and efficacy results of two large, randomized pivotal Phase III special protocol assessment trials, North American trial MM-009

The compound is being developed as a new and potentially safer means of targeting phosphodiesterase 4 (PDE4) to combat memory loss and cognitive deficits associated with Alzheimer’s disease

Laborie Medical Technologies said that it has been actively marketing T-DOC products with its urodynamics systems for several years in North America. T-DOC, along with Laborie’s line of

In her new role as president of Cell Therapeutics (CTI) Europe, Dr Waters, will accelerate the launch of Ap(3)ana, an organization that will seek to integrate new technologies